Fisher Asset Management’s Albany Molecular Research Inc AMRI Stock Holding History

Fisher Asset Management’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-184,589	Closed	-$4.01M	–	830
2017 Q2	$4.01M	Buy	184,589 +40,172	+28%	+$729K	0.01%	402
2017 Q1	$2.03M	Buy	144,417 +63,828	+79%	+$1.05M	﹤0.01%	438
2016 Q4	$1.51M	Sell	80,589 -77,205	-49%	-$1.31M	﹤0.01%	448
2016 Q3	$2.6M	Sell	157,794 -45,656	-22%	-$676K	﹤0.01%	423
2016 Q2	$2.93M	Hold	203,450	–	–	0.01%	426
2016 Q1	$3.33M	Hold	203,450	–	–	0.01%	406
2015 Q4	$4.04M	Buy	203,450 +32,574	+19%	+$619K	0.01%	369
2015 Q3	$2.98M	Buy	+170,876	New	+$3.48M	0.01%	385

Other funds holding AMRI

Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Fisher Asset Management's AMRI Position: Q3 2017 in Review

Fisher Asset Management sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 184,589 shares — an estimated $4.01M sold.

Fisher Asset Management first reported a position in AMRI in Q3 2015 and held it in 8 quarters. The position peaked at $4.04M in Q4 2015. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

Fisher Asset Management reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
Fisher Asset Management sold 184,589 Albany Molecular Research Inc shares in Q3 2017, an estimated $4.01M.
Fisher Asset Management first reported a position in Albany Molecular Research Inc in Q3 2015 and held it in 8 quarters.
Fisher Asset Management's Albany Molecular Research Inc position peaked at $4.04M in Q4 2015.
2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Fisher Asset Management's 13F filing for Q3 2017, filed 17 Oct 2017.